IntroductionThe prosthetic heart valves market has witnessed significant transformation over the past few decades, driven by ...

Edwards Lifesciences (NYSE: EW), a medical technology company specializing in artificial heart valves, currently trades at $67 per share, about 50% lower than the peak level of $131 seen in December ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $81.0, with a high ...

Vanguard Group Inc made a significant addition to its portfolio by acquiring 9,018,094 shares of Edwards Lifesciences Corp ...

The Galien Foundation recently announced the nominees for its "Best Medical Technology" Pix Galien USA awards.

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural ...

NYON, Switzerland, May 08, 2024--Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company ...

EW saw its stock trading at around $95 in June 2022, just before the Fed started increasing rates, and it’s still trading 30% ...

Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, expanding minimally invasive ...

Edwards Lifesciences Corporation (EW), headquartered ... the company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy ...